Corporate Governance - Corporate Officers
Ivan Gergel,
M.D., was appointed Executive Vice President, Research &
Development, in April 2008. Dr. Gergel has full responsibility
for all of the company’s R&D activities, including direct
supervision of clinical research, pre-clinical R&D, medical
affairs, marketed product development support, regulatory
affairs, project management and drug safety and surveillance.
From May 2005 until March 2008, Dr. Gergel was Senior Vice
President of Scientific Affairs and President of the Forest
Research Institute of Forest Laboratories Inc., managing over
900 physicians, scientists and staff at the Research Institute.
Prior to that, Dr. Gergel served as Vice President and Chief
Medical Officer at Forest and Executive Vice President of the
Forest Research Institute. He joined Forest in 1998 as Executive
Director of Clinical Research following nine years at SmithKline
Beecham, and was named Vice President of Clinical Development
and Clinical Affairs in 1999.
David P. Holveck was appointed
President, Chief Executive Officer, and a
Director of Endo in April 2008. Prior to
joining Endo, Mr. Holveck was President of
Johnson & Johnson Development Corporation
and Vice President, Corporate Development of
Johnson & Johnson since 2004. Mr. Holveck
joined Johnson & Johnson as a company Group
Chairman in 1999, following the acquisition
of Centocor, Inc., by Johnson & Johnson. Mr.
Holveck was Chief Executive Officer of
Centocor, Inc., at the time of the
acquisition. Mr. Holveck joined Centocor in
1983 and progressed through various
executive positions. In 1992, he assumed the
role of President and Chief Operating
Officer and later that year was named
President and Chief Executive Officer. Prior
to joining Centocor, he held positions at
General Electric Company, Corning Glass
Works, and Abbott Laboratories. Mr. Holveck
is a member of the Board of Trustees for the
Fund for West Chester University and the
Board of Directors of the Eastern Technology
Council as well as the Board of Directors of
Light Sciences Oncology, Inc.
Caroline B. Manogue
has served as Executive Vice President, Chief Legal Officer and Secretary since April 2004 and was previously Senior Vice President, General Counsel and Secretary since September 2000. Prior to joining Endo, Ms. Manogue was an Associate at the law firm Skadden, Arps, Slate, Meagher & Flom LLP since 1995. Edward J. Sweeney, in his
capacity as the company's Vice President, Controller, serves as the
company's Principal Accounting Officer. Mr. Sweeney has been Vice
President, Controller since June 2007 after having joined the
company in March 2004 as Director, Financial Reporting. Prior to
joining Endo, Mr. Sweeney was a Senior Manager at Ernest & Young LLP,
where he worked from September 1991 through March 2004. Mr. Sweeney
is a licensed certified public accountant in the Commonwealth of
Pennsylvania and holds a BS degree in Accounting from St. Joseph's
University.
Nancy J. Wysenski was
appointed Chief Operating Officer on September 6, 2007. Ms.
Wysenski, a 20-year veteran of the health care industry, most
recently was the President of EMD Pharmaceuticals, Inc., the U.S.
subsidiary of Germany-based Merck KGaA.
Prior
to joining and co-founding EMD as Vice President of Marketing and
Sales in 1999, Ms. Wysenski was the Senior Vice President of
Operations at NetGenics, a venture capital-backed, start-up company
specializing in technologies for drug discovery. Prior to that, Ms.
Wysenski held a number of positions of increasing scope and
responsibility at Astra Merck, culminating as Vice President of
Sales. During her tenure at Astra Merck, she also served on
the company’s operating board. Prior to joining Astra Merck in
1990, she began her pharmaceutical industry career in 1984 at Merck
Human Health where she held various positions of increasing
responsibility.
|
